Eli Lilly Delays Next-Gen Obesity Drug Filing to 2027

Eli Lilly (NYSE: LLY) announced Thursday that it will file for approval of its next-generation obesity drug retatrutide in the first quarter of 2027, a delay from the prior timeline that aimed for this year. The company cited the need for additional time to collect and verify manufacturing and quality-control data required by regulators.

The Product

Retatrutide is an investigational triple agonist (GLP-1/GIP/Glucagon) for obesity, showing significant weight loss in early clinical trials. It is considered a potential blockbuster in the rapidly growing obesity drug market.

Pricing and Availability

Eli Lilly has not disclosed pricing for retatrutide. Availability will depend on FDA approval, which could take several months after filing.

Competition

Retatrutide faces competition from existing obesity drugs like Wegovy (Novo Nordisk) and Lilly's own Mounjaro/Zepbound. Other companies, including Pfizer and Amgen, are developing similar treatments.

Potential Impact on Lilly

Retatrutide represents a significant opportunity for Lilly to expand its presence in the obesity market, projected to exceed $100 billion by 2030. The filing delay may give competitors time to catch up, but does not diminish the drug's long-term potential.